Clinical Trial Update: Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Autoinflammatory Disease

Drugs mentioned

• Lanadelumab (lanadelumab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Hereditary Autoinflammatory Disease | Phase 2 | Status: UNKNOWN